C A Z E N O V E Europe Equity Research 17 August 2026 AstraZeneca Clinically meaningful SAFFRON data for Tagrisso and Orpathys, and Enhertu DL04 success partially offset by discontinuation of eVOLVE-Lung02 for volrustomig This morning, Astra announced the results from three read-outs; (i) the SAFFRON trial for Tagrisso + Orpathys in 2L+ EGFRm NSCLC, which showed a statistically significant and clinically meaningful benefit on PFS and OS; (ii) the Destiny- Lung04 results for Enhertu, which showed a statistic ...